PCM
NVCR icon

Penserra Capital Management’s NovoCure NVCR Stock Holding History

Penserra Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,709
Closed -$8.14M – 1503
2021
Q2 		$8.14M Buy
+36,709
New +$7.14M 0.15% 186

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's NVCR Position: Q3 2021 in Review

Penserra Capital Management sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 36,709 shares — an estimated $8.14M sold.

Penserra Capital Management first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $8.14M in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Penserra Capital Management reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 36,709 NovoCure shares in Q3 2021, an estimated $8.14M.
  • Penserra Capital Management first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
  • Penserra Capital Management's NovoCure position peaked at $8.14M in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.